The Blue Box is in the Top20 Startup list for the #4YFN25 Awards: the highest official recognition offered exclusively to #startups during #MWC25. We are honoured to be recognised in the ✨ Digital Health Category: as a solution to enhance healthcare prevention, detection, and delivery across services, systems, and locations. Thank you! 4YFN & MWC Just like every year, we are delighted to reconnect with KOLs from around the globe and share our ongoing journey. Networking plays a pivotal role in our growth, bringing us closer to those from whom we can gain valuable insights and knowledge. 👉 Come meet us in the Awards Zone, Hall 8.0. 🗓️ March 3-6 📍 Barcelona #MWC25 #4YFN25 #4YFNAwards #Top20Startups 👁️ Check the full list on their website: https://lnkd.in/eFA7uYzQ
The Blue Box Biomedical Solutions
Fabricación de equipo médico
Barcelona, Catalonia 2788 seguidores
Breast cancer prevention, as easy as a pregnancy test.
Sobre nosotros
Women lack reliable breast cancer (BC) screening methods, as 50% of BCs are detected in a late-stage. At The Blue Box, we've developed a radiation-free, pain-free, low-cost device detecting BC in urine with 88.33%. This outperforms mammography by 15% across all age groups and by 30% for women under 50. By 2025, we aim to introduce this solution in gynecology clinics through a software-driven business model.
- Sitio web
-
http://thebluebox.ai
Enlace externo para The Blue Box Biomedical Solutions
- Sector
- Fabricación de equipo médico
- Tamaño de la empresa
- De 2 a 10 empleados
- Sede
- Barcelona, Catalonia
- Tipo
- De financiación privada
- Fundación
- 2021
- Especialidades
- Artificial intelligence, Breast cancer prevention, Machine Learning, Data gathering, Deep learning y Biomedical engineering
Ubicaciones
-
Principal
C. Pasqual i Vila
Barcelona, Catalonia 08029, ES
Empleados en The Blue Box Biomedical Solutions
-
Sara Morera Roca
Product Design & Biomedical Engineer
-
Lidia Navarro Farré, PhD
Building a urine-based Breast Cancer test – pain-free, radiation-free
-
Judit Giró Benet
Building a urine-based breast cancer test with a sensitivity of 88%
-
Júlia Solana Balaguer, PhD
Scientific & Clinical Lead | The Blue Box |📍Barcelona
Actualizaciones
-
🎉 We are officially part of the 🇪🇺 EIT Health Catapult program, in partnership with 🇩🇪 bioRN Life Science Cluster Rhine-Neckar, 🇩🇪 Medical Valley EMN e. V., and 🇫🇷 Capdigital. We will benefit from targeted training days, webinar series, and critical investor exposure. 🌐💡In 2024, Healthtech has emerged as the 5th largest venture capital investment category, trailing only behind heavyweights like Fintech, Energy, Biotech and Pharma. This growth is driven by the rising demand for innovative healthcare solutions, advances in technologies like AI and genomics, and the sector’s potential for long-term growth and returns. Notably, FemTech has experienced steady growth over the past decade. Furthermore, Barcelona, where we are based, ranks among the top 10 cities for investment in EMEA! Our mission in this program? To connect with the right people at the right time to secure the funding needed to bring The Blue Box to market. We're driven to transform healthcare, and with the right support, we're confident we can make a global impact. 🌍🔬
📢 Exciting News! EIT Health Catapult 2024-25 Semi-Finalists Announced! We’re thrilled to unveil the 29 groundbreaking start-ups selected for the semi-finals of the 9th edition of the EIT Health Catapult! They are: Aptadel Therapeutics, ArrayPatch Ltd, Cellectric Biosciences, Fusix Biotech GmbH, Immunofusion, Nūmi, PepKon, PoliRNA, Rejuversen, You2Yourself, Antegenes, BrightComSol, Brightmind.AI, CC Diagnostics, CheckEye, cureVision GmbH, Custom Surgical, FindAir, Galenband, Healshape, Kinetic Cortex, Lifebloom, mjn-neuro, NimBio, NIMBLE Diagnostics, PsyCurio, The Blue Box Biomedical Solutions, Tympany Medical , and VitalSigns Oy. These innovators, spanning life sciences and healthtech, are set to showcase their life-changing solutions to top industry experts, investors, and peers from across Europe. ✨ Key Highlights: - Semi-Final Presentations: 10 Life Sciences & 19 Healthtech start-ups will present to a public audience of healthcare professionals, investors, and experts. - Finals Announcement in April 2025: Top 9 start-ups (3 Life Sciences & 6 Healthtech) will advance to the finals, competing for a €30,000 prize and valuable in-kind support. - Major Prizes: Industry in-kind prizes totaling over €800,000 from top names like Amazon Web Services (AWS), eg technology Ltd, Lusíadas Saúde, AstraZeneca, and the prestigious "EIT Health Catapult Audience Alex Casta Award" 🏆 🎉 The EIT Health Catapult programme has a legacy of empowering start-ups with high-impact mentorship, rigorous business assessment, and unparalleled networking opportunities. Over eight editions, Catapult has supported 330+ companies in securing multi-million euro investments and vital support from key European partners. 👉 Stay tuned as these start-ups push boundaries, inspire change, and compete for Europe’s spotlight in healthcare innovation: https://lnkd.in/eudWYHEj #EITHealthCatapult #HealthcareInnovation #LifeSciences #Healthtech #StartUps
-
💪 Let’s kick off November with some promising news! The Biden administration's Cancer Moonshot initiative, in which we participated early this year, is ambitiously tackling the Breast Cancer burden aiming to reduce cancer deaths by at least 50% within 25 years. 👀 Key to this mission is early detection: the survival rate can reach 99% when breast cancer is caught early. 👏 The US admin is expanding access to critical screenings now available at no cost to women over 40. 😇 Our affordable and non-irradiating technology enables broader and more frequent screening, enabling the inclusion of a larger population in breast cancer screening, supporting the FDA's goal of expanding early detection. 💪💗 While there’s still work to do, we’re on a path to a future with fewer lives lost to breast cancer. Together, let’s raise awareness and support for all those fighting this disease. #BreastCancerAwarenessMonth #CancerMoonshot #EarlyDetection #WomensHealth https://lnkd.in/daADEzn6
Biden cancer initiative pushes for early breast cancer screenings
ny1.com
-
Every day is #WorldBreastCancerDay when you're building cool tech to help catch it early together with the dream team at Perdigó Medical! 💙 #BreastCancerAwareness #InnovationInAction
Today, we mark #WorldBreastCancerDay, a day to highlight the crucial role of early detection in improving outcomes and survival rates. At Perdigó Medical, we're proud to support innovations like The Blue Box Biomedical Solutions, whose groundbreaking non-invasive diagnostic tool is advancing early breast cancer detection. #BreastCancerAwareness #EarlyDetectionSaveLives
-
💪More than ever, we are fighting for women's health. We, as women—fifty percent of the global population!!—deserve accessible, low-cost, and accurate solutions specifically designed for us.🙆♀️ As a women-led and FOR women startup, we are on our way to making this a reality. No matter the challenges, we stand strong. Thanks for the mention The Guardian. Check out the article on the challenges the Femtech companies are facing by Amelia Hill. 👇
The ‘huge disadvantage’ women behind femtech phenomenon face
theguardian.com
-
Happy to announce that we’ve made it to the finals of the EIT Health Catapult Spain 🇪🇸 that will take place tomorrow in Santander. 💫 #EITHealthCatapult is an incredible training program that accelerates the development of the most promising European start-ups in life sciences and health tech. If we make it through the finals to the European program, we will be learning for two months from some of the best mentors and #healthcare leaders in Europe to take The Blue Box to the next level. 🚀 Stay tuned for more updates as we take on the finals and push forward in advancing health tech! #fightingbreastcancer #medtech #technologyforhealth #europeanleaders
-
The Blue Box Biomedical Solutions ha compartido esto
This is a pivotal moment in the fight against breast cancer, and we at The Blue Box Biomedical Solutions fully support the #FindItEarly movement, as every women deserves an appropriate breast cancer screening and care - no matter her breast density.💙 To address the alarming statistic that 50% of cancers in women with dense breasts go undetected🤯, we've developed The Blue Box, a device that uses urine biomarkers for early breast cancer detection - offering a non-invasive, non-image-based method that works for women with all types of breast tissue, ensuring no one is left behind in the fight against breast cancer. Let's work towards a future where every woman has access to the testing she needs! 🚀
🚨We are heading to Capitol Hill!🚨 We’re gearing up for a pivotal congressional hearing, and and this is your chance to be part of the change—no matter where you are! Here’s why this matters: - nearly 50% of American women have dense breast tissue! - If a woman has dense breast tissue and solely relies on 2D mammography or tomosynthesis, she's betting her life on a coin toss—mammograms miss 50% of cancer detections in dense breasts. - Women with dense breasts are 4 to 6 times more likely to develop breast cancer. (2017 UCSF study cites Dense Breasts risk higher than all other breast cancer risk factors.) - Despite these alarming facts, insurance companies only cover a portion of the necessary screenings, leaving many women without the adequate care they need. This has to change. This is why we’re pushing for the Find It Early Act—to ensure no woman is left behind in the fight against breast cancer. But we can’t do it alone. Here’s how you can be the ultimate Thriver Advocate from wherever you are: 1️⃣ Send a Letter: Visit your Rep’s and Senators’ websites, click “Contact Us,” and tell them why this issue is personal to you. Use the stats above to emphasize the importance of comprehensive screening coverage. 2️⃣ Find Your Rep: Go to https://www.house.gov/ , enter your zip code, and contact your Rep to make your voice heard. 3️⃣ Set Up a Zoom Call: Call the Capitol Switchboard, ask for your rep or Senator’s office, and request a 30-minute Zoom call with the Health Staffer. Explain why they should co-sponsor the Find It Early Act. We’re making history on Capitol Hill—Let’s ensure no woman is left to bet on a coin toss regarding her health. Together, we can change the future of breast cancer detection. Let’s make history! ccing amazing breast health partners & advocates: Liz Powell Andrea Wolf Sally Wolf Miranda Franco Vanessa Joy Walker Leslie Ferris Yerger Clare Dowling Dougherty Sheila Ann Mikhail Madeline Stickley Katie Collins Smita A. Kaitlin Christine Ally Parnes, M.D. Shadi Saberi Kimberly Sharp Olivier Roy, PhD Vicky Word Marissa Fayer Robin Farmanfarmaian Sherri Douville Sara Vaughn, MD Gerald Farrokh Daneshvar, M.D. Rohit Jain Robyn Coward Jessmy DSouza Susan Akbarpour Maryam Ziaei, PhD Maryam Naghavi Golnaz (Naz) Moeini Bita Daryabari Tanya Roosta, Ph.D., MFE Reema Khan The White House Office of Congresswoman Anna G. Eshoo #FindItEarly #AdvocateForChange #ThriverAdvocate #CapitolHill
-
🙌 CancerX Moonshot has officially come to an end. 📚 We have learned about patient engagement strategies with Savvy Cooperative, discussed Advocate Health’s perspective on the future of health with Rasu Shrestha MD MBA, explored bringing cancer care closer to home with Ruben Mesa, MD from Atrium Health, and delved into data strategy and partnership approaches with Tim Arnold from Advocate Health. Michael K. Giannopoulos and Matthew Powers from Dell Technologies, our champion, guided us through best practices in AI and data management, while Andrea Downing from Light Collective provided insights into AI guardrails. We also learned about reimbursement strategy with Foley & Lardner LLP, and heard from American Cancer Society BrightEdge Fund about their work in impact investing. Finally, we had the chance to e-meet with representatives from the Office of the National Coordinator for Health IT, which manages health IT policies and programs for the U.S. Federal Government. Christa Bogdanow from MassChallenge and Beth Andrews from Dell Technologies guided us through the entire program and supported us in every aspect we needed. 🚀 What an incredible journey! Thank you all for your time and efforts in helping startups build the next era of healthcare!
-
👁️ Check out the latest episode of BioEmprendedores where our CEO, Judit Giró Benet, and the CEO of Perdigó Medical's, Arnau Perdigó-Oliveras were interviewed. 💫 BioEmprendedores is the go-to #podcast for biotech, health and medtech entrepreneurship hosted by Rosendo Garganta & Oscar Porcel ⬇️ We chatted about innovating in the medical industry, the need of understanding of the product's clinical value and to have a strong positioning strategy, and great partners—like we do with Perdigó Medical. 🎉 Thanks for having us!! Youtube: https://lnkd.in/dCxG8tqR Ivoox: https://lnkd.in/dhyYtkYs Spotify: https://lnkd.in/d5kDM_Q4
-
🧐🧠Understanding how The Blue Box can fit into other healthcare systems in Europe is one of our main objectives for 2024. Happy to participate in the first edition in Spain from one of the top Medtech events in France! #HealthcareInnovation #HealthTech #MedicalDevices
🚀 Nous avons le plaisir de vous annoncer les 9 finalistes du Concours de l’Innovation 2024 ! Félicitations aux start-ups qui auront l'honneur de présenter leurs projets lors de la 1ère édition de Medi'Nov Connection Spain : - Enrique Llaudet Carles, Ephion Health - Javier Jiménez, Kriba - Nuria Antolí, NURA TECHNOLOGY SL - Judit Giró Benet, The Blue Box Biomedical Solutions - Eduardo W. Jørgensen de Vizcarrondo, Medicsen - Laetitia Lebert, Medinbox - Szilvia Endrényi, Rethink Medical SL. - Julien FINCI, Aspivix - Nathalie Vandenbroucke, Dendris Ne manquez pas leurs présentations le mercredi 26 juin, de 17h00 à 18h00, au WTC de Barcelone ! 🚀 We are delighted to announce the 9 finalists in the 2024 Innovation Competition ! Congratulations to the start-ups who will have the honour of presenting their projects at the 1st edition of Medi'Nov Connection Spain. Don't miss their presentations on Wednesday 26 June, from 17:00 to 18:00, at the WTC of Barcelona ! #Innovation #Medtech #Startup
Páginas similares
Buscar empleos
Financiación
Última ronda
Semilla540.631,00 US$
Inversores
Grow Venture Partners